Following on from our attendance at ISPOR International in Montreal, Canada in May, we are delighted to share our report.
We are delighted to have run an issue panel at ISPOR 2025. The details of this session can be found below:
Following the IRA’s 2022 roll-out, there was a knee-jerk reaction by some stakeholders to suspend clinical programmes in rare diseases. The National Organisation for Rare Disorders subsequently declared in an open 2023 letter to the Centers for Medicare and Medicaid Services (CMS) that the IRA could inadvertently reduce investment and, subsequently, access to rare disease therapies. Three years after the IRA’s introduction, this issue panel will address to what extent these concerns will impact investment, access, and pricing in rare diseases.
We were delighted to presented 6 research posters at ISPOR 2025. The titles of our research are listed below, alongside the poster session dates and times.
Wednesday
14 May
Thursday
15 May
Friday
16 May
